Hamadeh Tarazi

Hamadeh Tarazi

Auto-generated profile, based on publicly available information

Hamadeh Tarazi

Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2010 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
YBYasser Bustanji
Yasser Bustanji
IAIhab M. Al-Masri
Ihab M. Al-Masri
MMMohammad Mohammad
Mohammad Mohammad
MHMohammad Hudaib
Mohammad Hudaib
KTKhaled Tawaha
Khaled Tawaha
HAHatim S AlKhatib
Hatim S AlKhatib
The prevalence of obesity is increasing at an alarming rate, but, unfortunately, only a few drugs are currently available on the market. In the present study, the methanolic extract of Ginkgo biloba L. (Ginkgoaceae) was investigated as an inhibitor of pancreatic lipase (PL) in an attempt to explain its hypolipidaemic activity. In vitro assay of G. biloba leaves extract revealed a substantial PL inhibition activity (IC50 = 16.5 µg/mL). Further investigation was performed by employing theoretical docking simulations and experimental testing to uncover the active constituents responsible for G. biloba anti-lipase activity. Virtually, terpene trilactones, including ginkgolides and bilobalide, were found to fit within the binding pocket of PL via several attractive interactions with key amino acids. Experimentally, ginkgolides A, B, and bilobalide were found to inhibit PL significantly (IC50 = 22.9, 90.0, and 60.1 µg/mL, respectively). Our findings demonstrated that the hypolipidaemic effects of G. biloba extract can be attributed to the inhibition of PL by, at least in part, terpene trilactones. In conclusion, this work can be considered a new step towards the discovery of new natural safe hypolipidaemic PL inhibitors.

16 November 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AAAla’a Al-Hrout
Ala’a Al-Hrout
ACAmphun Chaiboonchoe
Amphun Chaiboonchoe
BKBasel Khraiwesh
Basel Khraiwesh
CMChandraprabha Murali
Chandraprabha Murali
BBBadriya Baig
Badriya Baig
AAAmr Amin
Amr Amin
Poor prognoses remain the most challenging aspect of hepatocellular carcinoma (HCC) therapy. Consequently, alternative therapeutics are essential to control HCC. This study investigated the anticancer effects of safranal against HCC using in vitro, in silico, and network analyses. Cell cycle and immunoblot analyses of key regulators of cell cycle, DNA damage repair and apoptosis demonstrated unique safranal-mediated cell cycle arrest at G2/M phase at 6 and 12 h, and at S-phase at 24 h, and a pronounced effect on DNA damage machinery. Safranal also showed pro-apoptotic effect through activation of both intrinsic and extrinsic initiator caspases; indicating ER stress-mediated apoptosis. Gene set enrichment analysis provided consistent findings where UPR is among the top terms of up-regulated genes in response to safranal treatment. Thus, proteins involved in ER stress were regulated through safranal treatment to induce UPR in HepG2 cells.

5 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MEMohammed El-Gamal
Mohammed El-Gamal
NMNada H. Mewafi
Nada H. Mewafi
NANada E. Abdelmotteleb
Nada E. Abdelmotteleb
MEMinnatullah A. Emara
Minnatullah A. Emara
HTHamadeh Tarazi
Hamadeh Tarazi
HAHanan S. Anbar
Hanan S. Anbar
HER4 is a receptor tyrosine kinase that is required for the evolution of normal body systems such as cardiovascular, nervous, and endocrine systems, especially the mammary glands. It is activated through ligand binding and activates MAPKs and PI3K/AKT pathways. HER4 is commonly expressed in many human tissues, both adult and fetal. It is important to understand the role of HER4 in the treatment of many disorders. Many studies were also conducted on the role of HER4 in tumors and its tumor suppressor function. Mostly, overexpression of HER4 kinase results in cancer development. In the present article, we reviewed the structure, location, ligands, physiological functions of HER4, and its relationship to different cancer types. HER4 inhibitors reported mainly from 2016 to the present were reviewed as well.

15 July 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MSMaha Saber-Ayad
Maha Saber-Ayad
SHSarah Hammoudeh
Sarah Hammoudeh
EAEman Abu-Gharbieh
Eman Abu-Gharbieh
Rifat HamoudiRifat Hamoudi
Rifat Hamoudi
HTHamadeh Tarazi
Hamadeh Tarazi
QHQutayba Hamid
Qutayba Hamid
The emergence of the COVID-19 pandemic has mandated the instant (re)search for potential drug candidates. In response to the unprecedented situation, it was recognized early that repurposing of available drugs in the market could timely save lives, by skipping the lengthy phases of preclinical and initial safety studies. BenevolentAI’s large knowledge graph repository of structured medical information suggested baricitinib, a Janus-associated kinase inhibitor, as a potential repurposed medicine with a dual mechanism; hindering SARS-CoV2 entry and combatting the cytokine storm; the leading cause of mortality in COVID-19. However, the recently-published Adaptive COVID-19 Treatment Trial-2 (ACTT-2) positioned baricitinib only in combination with remdesivir for treatment of a specific category of COVID-19 patients, whereas the drug is not recommended to be used alone except in clinical trials. The increased pace of data output in all life sciences fields has changed our understanding of data processing and manipulation. For the purpose of drug design, development, or repurposing, the integration of different disciplines of life sciences is highly recommended to achieve the ultimate benefit of using new technologies to mine BIG data, however, the final say remains to be concluded after the drug is used in clinical practice. This review demonstrates different bioinformatics, chemical, pharmacological, and clinical aspects of baricitinib to highlight the repurposing journey of the drug and evaluates its placement in the current guidelines for COVID-19 treatment.

1 June 2017 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SISaleh Ihmaid
Saleh Ihmaid
HAHany E.A. Ahmed
Hany E.A. Ahmed
AAAdeeb Al-Sheikh Ali
Adeeb Al-Sheikh Ali
YSYousery E. Sherif
Yousery E. Sherif
HTHamadeh M. Tarazi
Hamadeh M. Tarazi
HRHeba Rateb
Heba Rateb

27 June 2018 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
CVCijo George Vazhappilly
Cijo George Vazhappilly
ESEkram Saleh
Ekram Saleh
WRWafaa Ramadan
Wafaa Ramadan
VMVarsha Menon
Varsha Menon
AAAya Mudhafar Al-Azawi
Aya Mudhafar Al-Azawi
RERaafat El-Awady
Raafat El-Awady